Welcome to Paid Research Studies




  • Condition:   Niemann-Pick Disease, Type C1
    Intervention:   Drug: Hydroxypropyl-β-cyclodextrin
    Sponsor:   CTD Holdings, Inc.
    Recruiting

  • Condition:   Methods of Exercise in Children
    Intervention:   Other: Exercise Training
    Sponsor:   Shlomit Aizik
    Recruiting

  • Condition:   Niemann-Pick Disease, Type C1
    Intervention:   Drug: Hydroxypropyl-beta-cyclodextrin
    Sponsor:   CTD Holdings, Inc.
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Retinoblastoma
    Interventions:   Drug: vincristine;   Drug: topotecan;   Drug: filgrastim;   Drug: PEG-filgrastim;   Drug: carboplatin;   Other: focal therapy;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: MESNA;   Drug: doxorubicin;   Procedure: enucleation;   Radiation: external beam radiation or proton beam radiation
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Recurrent Gastric Adenocarcinoma;   Recurrent Gastroesophageal Junction Adenocarcinoma
    Interventions:   Drug: Cyclophosphamide;   Biological: IRX-2;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Obstructive Pulmonary Disease;   Pulmonary Artery Hypertension;   Heart Failure;   Hypertension
    Interventions:   Other: Maximum Exercise Tests;   Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate;   Drug: BQ-123;   Drug: Fexofenadine, Ranitidine;   Other: Angiotensin-II, Valsartan;   Drug: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine;   Drug: BQ-123, MitoQ, BH4
    Sponsor:   Russell Richardson
    Recruiting

  • Condition:   Adult Solid Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Brain Neoplasm;   Recurrent Malignant Solid Neoplasm;   Refractory Brain Neoplasm
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Temsirolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   CD22 Positive;   Minimal Residual Disease;   Progressive Disease;   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Non-Hodgkin Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   CD19 Positive;   Chronic Lymphocytic Leukemia;   Minimal Residual Disease;   Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm Oncology
    Not yet recruiting

  • Conditions:   Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation;   Recurrent Lip and Oral Cavity Carcinoma;   Recurrent Malignant Endocrine Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Male Reproductive System Neoplasm;   Recurrent Malignant Mesothelioma;   Recurrent Malignant Neoplasm of Multiple Primary Sites;   Recurrent Malignant Oral Neoplasm;   Recurrent Malignant Pharyngeal Neoplasm;   Recurrent Malignant Skin Neoplasm;   Recurrent Malignant Soft Tissue Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Malignant Thyroid Gland Neoplasm;   Recurrent Malignant Urinary System Neoplasm;   Recurrent Melanoma of the Skin;   Refractory Cutaneous Melanoma;   Refractory Malignant Bone Neoplasm;   Refractory Malignant Endocrine Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm;   Refractory Malignant Male Reproductive System Neoplasm;   Refractory Malignant Mesothelioma;   Refractory Malignant Neoplasm of Multiple Primary Sites;   Refractory Malignant Oral Neoplasm;   Refractory Malignant Pharyngeal Neoplasm;   Refractory Malignant Skin Neoplasm;   Refractory Malignant Soft Tissue Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Malignant Thyroid Gland Neoplasm;   Refractory Malignant Urinary System Neoplasm
    Interventions:   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Decitabine;   Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes;   Other: Laboratory Biomarker Analysis
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Hepatocellular Carcinoma;   Refractory Liver Carcinoma;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8
    Interventions:   Drug: Cyclophosphamide;   Biological: Cytokine-based Biologic Agent IRX-2;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Janssen Scientific Affairs, LLC
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Immunoglobulin Heavy Chain Locus Variable Region Mutation;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
    Not yet recruiting

  • Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   PSCA Positive
    Interventions:   Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   SLAMF7 Positive
    Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Synovial Sarcoma;   Myxoid Liposarcoma;   HLA-A*0201 Positive Cells Present;   NY-ESO-1 Positive Tumor Cells Present;   Recurrent Myxoid Liposarcoma;   Recurrent Synovial Sarcoma
    Interventions:   Biological: Aldesleukin;   Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Dendritic Cell-targeting Lentiviral Vector ID-LV305;   Drug: Immunotherapeutic Combination Product CMB305
    Sponsors:   M.D. Anderson Cancer Center;   Immune Design;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   TNFRSF17 Positive
    Interventions:   Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Juno Therapeutics, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anemia;   ASXL1 Gene Mutation;   EZH2 Gene Mutation;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Plasma Cell Myeloma;   Primary Myelofibrosis;   Recurrent Plasma Cell Myeloma;   Secondary Myelofibrosis;   Thrombocytopenia
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   HLA-A*24:02 Positive Cells Present;   Metastatic Uveal Melanoma;   Uveal Melanoma Metastatic in the Liver
    Interventions:   Biological: Aldesleukin;   Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes;   Drug: Cyclophosphamide;   Biological: Ipilimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Metastatic Cholangiocarcinoma;   Metastatic Colorectal Carcinoma;   Metastatic Digestive System Carcinoma;   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IV Esophageal Cancer AJCC v7;   Stage IV Gastric Cancer AJCC v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Biological: Adoptive Immunotherapy;   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Amyloidosis;   Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Recurrent Primary Amyloidosis
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Multiple Myeloma Research Consortium
    Recruiting

  • Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Oligometastasis;   Ovarian Carcinosarcoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Osteosarcoma;   Recurrent Ovarian Carcinoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma
    Interventions:   Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Interleukin-2;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Biological: BCMA-specific CAR-expressing T Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Gamma-Secretase Inhibitor LY3039478;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   COL6A3 Positive;   HLA-A*0201 Positive Cells Present;   PRAME Positive;   Recurrent Ovarian Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: CD8-Positive T-Lymphocyte;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Aldesleukin;   Biological: CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: NGFR-transduced Autologous T Lymphocytes;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ERBB2 Gene Amplification;   Estrogen Receptor Positive;   Inflammatory Breast Carcinoma;   Metastatic Breast Carcinoma;   Progesterone Receptor Positive;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Neratinib;   Drug: Paclitaxel;   Biological: Pertuzumab;   Biological: Trastuzumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Puma Biotechnology, Inc.
    Recruiting

  • Conditions:   Composite Lymphoma;   Grade 3b Follicular Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage I Follicular Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage II Follicular Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage III Follicular Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma;   Stage IV Follicular Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bone Sarcoma;   Dedifferentiated Chondrosarcoma;   Giant Cell Tumor of Bone;   Malignancy in Giant Cell Tumor of Bone;   Ovarian Carcinosarcoma;   Platinum-Resistant Ovarian Carcinoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma;   Soft Tissue Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Biological: Aldesleukin;   Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   Iovance Biotherapeutics, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent T Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia;   Refractory T Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Indolent Non-Hodgkin Lymphoma;   Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Nivolumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Kami Maddocks;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting

  • Conditions:   CD20 Positive;   Mantle Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Ibrutinib;   Drug: Methotrexate;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AIDS-Related Burkitt Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Burkitt Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Burkitt Lymphoma;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Ofatumumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia With BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Drug: Ponatinib;   Biological: Rituximab;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Secondary Myelofibrosis;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Blasts 15 Percent or Less of Bone Marrow Nucleated Cells;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Ofatumumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Ponatinib;   Drug: Ponatinib Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Burkitt Leukemia;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Burkitt Leukemia;   Recurrent Burkitt Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Acute Lymphoblastic Leukemia;   Refractory Burkitt Leukemia;   Refractory Burkitt Lymphoma;   Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   Refractory Lymphoblastic Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Ofatumumab;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate Liposome
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Venetoclax;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride;   Drug: Cyclophosphamide;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With Gene Mutations;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   B-Cell Non-Hodgkin Lymphoma;   CD20 Positive;   Diffuse Large B-Cell Lymphoma Unclassifiable;   Intravascular Large B-Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Biological: Nivolumab;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   Bristol-Myers Squibb (BMS);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia;   Donor
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Bilateral Breast Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma;   Unilateral Breast Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine;   Other: Placebo;   Biological: Sargramostim
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Angioimmunoblastic T-Cell Lymphoma;   Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Recurrent Malignant Neoplasm;   Refractory Malignant Neoplasm
    Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Eribulin Mesylate;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Biological: Nivolumab;   Drug: Olaparib;   Drug: Oxaliplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Drug: Pemetrexed Disodium;   Drug: Selinexor;   Drug: Topotecan Hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AIDS-Related Lymphoma;   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   CD20 Negative;   CD20 Positive;   Human Immunodeficiency Virus Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Prednisone;   Drug: Umbralisib;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   KMT2A Gene Rearrangement;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Blasts More Than 25 Percent of Bone Marrow Nucleated Cells;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   Systemic Scleroderma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Papillary Ependymoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting